Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240031/S003

Neuspera Sacral Neuromodulation (SNM) System

Neuspera Medical, Inc. · Decision date Apr 21, 2026

FDA DECISIONP240031/S003

What did the FDA approve?

FDA records P240031/S003 as a supplement to PMA P240031, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Apr 21, 2026.

FDA approval order statement

approval for the addition of the Neuspera Wearable
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Gastroenterology, Urology
Decision date
Apr 21, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P240031/S003
Regulatory pathway
PMA supplement
Product code
EZW
Decision code
APPR
Decision date
Apr 21, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, electrical, implantable, for incontinence.

Product code
EZW
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P240031/S001 · Related supplement

    Neuspera Sacral Neuromodulation System

  2. P240031/S003 received

    Application receipt date recorded by FDA.

  3. P240031/S004 · Related supplement

    Neuspera Sacral Neuromodulation (SNM) System

  4. P240031/S003 · FDA decision

    Normal 180 Day Track

  5. P240031/S005 · Related supplement

    Neuspera Sacral Neuromodulation (SNM) System

Timeline entries are records held by MedtechLedger for P240031. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240031

Product / regulatory recordCompanyPathwayDecision dateSource
Neuspera Medical, Inc.PMA supplementAug 15, 2025FDA
Neuspera Medical, Inc.PMA supplementApr 3, 2026FDA
Neuspera Medical, Inc.PMA supplementAug 21, 2026FDA

Explore the linked device profile

Other records with product code EZW

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Neuspera Medical, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
51 Daggett Dr., San Jose, CA, 95134

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records